Article

Envisioning a clear plan for diagnosis of ocular sarcoidosis

Oral corticosteroid therapy is essential for ocular sarcoidosis. A sub-Tenon's triamcinolone infusion, however, is useful for older patients to avoid the side effects of corticosteroids. Managing ocular sarcoidosis often requires vitrectomy for fibrotic lesions and photocoagulation for ischemic retinopathy and macroaneurysms, said Nobuyuki Ohguro, MD, Osaka University Medical School, Osaka, Japan.

Oral corticosteroid therapy is essential for ocular sarcoidosis. A sub-Tenon's triamcinolone infusion, however, is useful for older patients to avoid the side effects of corticosteroids. Managing ocular sarcoidosis often requires vitrectomy for fibrotic lesions and photocoagulation for ischemic retinopathy and macroaneurysms, said Nobuyuki Ohguro, MD, Osaka University Medical School, Osaka, Japan.

When the first international workshop on ocular sarcoidosis was held in the fall 2007 in Tokyo, uveitis specialists from around the world and two pulmonologists who specialize in sarcoidosis identified seven signs of intraocular inflammation that suggest a diagnosis of ocular sarcoidosis: mutton-fat/granulomatous keratic precipitates and/or iris nodules; trabecular meshwork nodules and/or tent-shaped peripheral anterior synechiae; snowballs/string-of-pearls vitreous opacities; multiple chorioretinal peripheral lesions; nodular and/or segmental periphlebitis and/or a retinal macroaneurysm in an inflamed eye; optic disc nodule(s)/granuloma(s) and/or solitary choroidal nodule; and bilateral disease.

Dr. Ohguro said that five tests are useful to reach a definitive diagnosis: a negative tuberculin test in a patient with a bacille Calmette-Guérin vaccination or in a patient with a previous positive tuberculin skin test, elevated serum angiotensin converting enzyme value and/or elevated serum lysozyme value, a positive chest X-ray showing bilateral hilar lymphadenopathy (BHL), abnormal liver enzyme tests, and a chest computed tomography scan in patients with a negative chest x-ray.

Diagnostic criteria were determined based on ocular signs, investigational tests, and biopsy results reaching four levels of diagnostic certainty:

  • Definite ocular sarcoidosis was indicated by a biopsy-supported diagnosis with compatible uveitis.
  • Presumed ocular sarcoidosis described cases without a biopsy but with BHL with a compatible uveitis.
  • Probable ocular sarcoidosis indicated cases without a biopsy, a chest x-ray without BHL, three suggestive intraocular signs, and two positive tests.
  • Possible ocular sarcoidosis was indicated by a negative lung biopsy and at least four suggestive intraocular signs with at least two positive tests.

"The gold standard for diagnosing sarcoidosis was previously histopathologic proof using biopsy tissue," Dr. Ohguro said. "However, biopsy of intraocular tissue is not common and is unacceptable to patients with uveitis unless the tissue is obtained from an easily accessible site. The Tokyo Diagnostic Criteria is the first international diagnostic criteria for ocular sarcoidosis based on combined ophthalmic clinical signs and laboratory investigations without evident systemic involvement. Further discussion and prospective validation studies are needed."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.